Novartis planning 14 OTC brand sale to "streamline" portfolio: Acutrim, Fiberall on block.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS LOOKING TO SELL ACUTRIM, FIBERALL, 12 OTHER OTC BRANDS TO "STREAMLINE" product sales, the company said Jan. 13. Newly-formed Novartis is putting the 14 products on the block "as part of a strategic plan to streamline its current OTC product portfolio" so it can "focus on key brands following its merger." The marriage of Ciba and Sandoz to form Summit, N.J.-based Novartis was completed Dec. 20 ("The Tan Sheet" Dec. 23, 1996, p. 26).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning